Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Cash & Equivalents (2022 - 2025)

Prokidney (PROK) has disclosed Cash & Equivalents for 4 consecutive years, with $95.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 11.81% to $95.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $95.3 million, a 11.81% decrease, with the full-year FY2024 number at $99.1 million, up 63.43% from a year prior.
  • Cash & Equivalents was $95.3 million for Q3 2025 at Prokidney, up from $84.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $506.3 million in Q3 2022 to a low of $60.6 million in Q4 2023.
  • A 4-year average of $196.0 million and a median of $108.1 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 87.63% in 2023, then surged 63.43% in 2024.
  • Prokidney's Cash & Equivalents stood at $490.3 million in 2022, then crashed by 87.63% to $60.6 million in 2023, then soared by 63.43% to $99.1 million in 2024, then dropped by 3.83% to $95.3 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's Cash & Equivalents are $95.3 million (Q3 2025), $84.9 million (Q2 2025), and $97.8 million (Q1 2025).